Syntagon to open Shanghai operation
Scandinavian drug development company Syntagon is to expand its global presence by opening new premises in Shanghai. The expansion is set to bolster Syntagon's raw material sourcing capabilities - often a considerable cost element in clinical API production.
Scandinavian drug development company Syntagon is to expand its global presence by opening new premises in Shanghai. The expansion is set to bolster Syntagon's raw material sourcing capabilities - often a considerable cost element in clinical API production.
"Our Shanghai office will allow us to source high quality raw materials at competitive rates; savings we will then be able to pass on to our clients," says Syntagon ceo Michael Lofthagen.
The Shanghai office will have direct access to a broader choice of raw material suppliers that will allow Syntagon to deliver materials more rapidly at more attractive prices.
The Shanghai offices will compliment Syntagon's existing operations in Soedertaelje, Sweden, and Riga, Latvia.
Syntagon develops compounds from lead optimisation to phase II clinical trials using the latest technology and equipment combined with a solid quality system.
